Ezra Cohen to Risk Assessment
This is a "connection" page, showing publications Ezra Cohen has written about Risk Assessment.
Connection Strength
0.157
-
Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy. Head Neck. 2009 Aug; 31(8):1013-21.
Score: 0.051
-
Mechanisms of resistance to EGFR inhibitors in head and neck cancer. Head Neck. 2009 Aug; 31(8):1086-94.
Score: 0.051
-
Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. JAMA Oncol. 2016 Feb; 2(2):209-16.
Score: 0.020
-
Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2008 Oct; 134(10):1060-5.
Score: 0.012
-
Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma. Ann Oncol. 2008 Sep; 19(9):1650-4.
Score: 0.012
-
Planned post-chemoradiation neck dissection: significance of radiation dose. Laryngoscope. 2006 Jan; 116(1):33-6.
Score: 0.010